Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 99

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 99
---
 of Merger entered into a termination agreement (the “ Termination Agreement”),
pursuant to which the parties agreed to terminate the Agreement and Plan of Merger on the date thereof (the “ Termination Date”),
and such agreement became null and void and of no further force or effect.

On April 8, 2024, CGY Investments
Limited and DSF Investment Holdings Limited voluntarily converted 401,537 Class B Ordinary Shares and 45,305 Class B Ordinary Shares,
respectively into Class A Ordinary Shares on a one-for-one basis. Upon conversion, 1,796,934 Class B Ordinary Shares were issued and outstanding,
CGY Investments Limited owned 533,575 Class A Ordinary Shares and did not own any Class B Ordinary Share; and DSF Investment Holdings
Limited owned 45,305 Class A Ordinary Shares and did not own any Class B Ordinary Share.

On January 2, 2025, the Company
entered into a certain securities purchase agreement with certain non-affiliated institutional investors pursuant to which the Company
sold 1,535,000 Class A ordinary shares of the Company, par value $0.00001 per share at a per share price of $2.00 in a registered direct
offering, for gross proceeds of $3,070,000.

Over the past three years,
we have invested approximately$0.2 milliontowards our principal capital expenditures,
which include laboratory equipment, leasehold improvements, and other equipment.

The following diagram illustrates
our corporate structure as of the date of this annual report:

Note 1: Dr. Clark Cheng, a
former Executive Director of Aptorum Group, holds the remaining 10% shareholding of Aptorum Medical Limited.

Note 2: Angen Funds Limited,
a company designated by an investor of ALS series projects, holds the remaining 20% shareholding of Acticule Life Sciences Limited.

Note 3: Accelerate
Technologies Pte. Ltd., the commercialization arm of the Singapore Agency for Science, Technology and Research
(“ A*STAR”), hold 15% shareholding of Paths Diagnostics Pte. Limited. The inventors of PathsDxTest
technologies in A*STAR hold the remaining 10% of shareholding of Paths Diagnostics Pte. Limited.

Note 4: An investor of project
VLS-2 holds the remaining 10% shareholding of mTor (Hong Kong) Limited.

Currently, we conduct the
majority of our operations through